CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

57.34 +1.91 (+3.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

31 32 33 34 35 36 37 38 Next >

Why CRISPR Therapeutics Stock Is Falling ↗

June 22, 2022

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.

Via Benzinga

Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know ↗

June 22, 2022

Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over...

Via Benzinga

Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗

June 22, 2022

Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.

Via Talk Markets

CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock ↗

June 16, 2022

On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr.

Via Benzinga

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases? ↗

June 13, 2022

Crispr and Vertex tested their gene-edited drug in two blood diseases.

Via Investor's Business Daily

Analyst Ratings for CRISPR Therapeutics ↗

June 13, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

93 Biggest Movers From Yesterday ↗

June 14, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...

Via Benzinga

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive ↗

June 13, 2022

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic...

Via Benzinga

70 Stocks Moving In Monday's Mid-Day Session ↗

June 13, 2022

Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...

Via Benzinga

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

June 11, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing ↗

June 10, 2022

The company is using a different approach to tackle the blood disease.

Via Investor's Business Daily

7 No-Brainer Biotech Stocks to Add to Your Buy List ↗

June 09, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

Via InvestorPlace

7 Oversold Stocks to Buy Right Now ↗

June 08, 2022

Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price.

Via InvestorPlace

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

June 02, 2022

From Vertex Pharmaceuticals Incorporated

Via Business Wire

IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize ↗

June 01, 2022

One analyst expects multiple new drug launches between 2024-26.

Via Investor's Business Daily

Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks ↗

May 20, 2022

Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside.

Via Talk Markets

Why Orphan Drug Designation Offers Several Benefits

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...

Via FinancialNewsMedia

Analyst Ratings for CRISPR Therapeutics ↗

May 17, 2022

Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

How to Buy Stocks in a Recession ↗

May 16, 2022

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

Via InvestorPlace

5 Cathie Wood Stocks to Buy Now ↗

May 16, 2022

ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.

Via InvestorPlace

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis ↗

May 12, 2022

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

Via Investor's Business Daily

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗

May 10, 2022

Via Benzinga

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗

May 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

April 28, 2022

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Via Benzinga

3 Cathie Wood Stocks to Count on in Q2 ↗

April 26, 2022

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility.

Via InvestorPlace

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗

April 20, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

April 01, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a...

Via Benzinga

3 Best Stocks to Trade Right Now ↗

March 24, 2022

Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative.

Via InvestorPlace

< Previous 1 2

...

31 32 33 34 35 36 37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.